Timmy Nguyen

In this episode of The Moonlight Shift, Gina Mauro sits down with Andrew Evens, DO, MBA, MSc, SVP, who serves as chief medical officer of Oncology Services, RWJBarnabas Health Medical Group and RWJBarnabas Health; deputy director for clinical services and chief physician officer of Rutgers Cancer Institute and the Jack & Sheryl Morris Cancer Center, associate vice chancellor of Clinical Innovation & Data Analytics, Rutgers Health, and professor of medicine of Rutgers Robert Wood Johnson...

Diarrhea remains a primary distinguishing toxicity associated with NALIRIFOX (liposomal irinotecan [Onivyde], oxaliplatin, fluorouracil, and leucovorin) relative to other frontline regimens for metastatic pancreatic cancer. Managing it effectively can determine whether a patient stays on treatment long enough to derive benefit. In the phase 3 NAPOLI-3 trial (NCT04083235), more than half of patients receiving liposomal irinotecan required some type of dose reduction.

Opinion|Videos|August 21, 2026 Author(s)Rachna T. Shroff, MD, MS, FASCO, James J. Harding, MD, Lipika Goyal, MD In the third debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a Child-Pugh A, BCLC stage B patient eligible for locoregional therapy, asking whether clinicians should prioritize locoregional treatment or introduce systemic therapy earlier.